Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LHCGR | P22888 | 9/20 | 0.60 |
| ▸ | FSHR | P23945 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | BRAF | P15056 | 9/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026955 | 0.93 | BRAF (0.57) | LHCGRFSHRTSHRBRAFPDE4A | |
| SCHEMBL5024555 | 0.88 | LHCGR (0.55) | LHCGRFSHRTSHRBRAFPDE4A | |
| SCHEMBL5030974 | 0.87 | LHCGR (0.53) | LHCGRFSHRTSHRBRAFPDE4A | |
| SCHEMBL6222004 | 0.86 | LHCGR (0.68) | LHCGRFSHRTSHRBRAF | |
| SCHEMBL4421622 | 0.84 | LHCGR (0.60) | LHCGRFSHRTSHRBRAFPDE4A | |
| SCHEMBL4425074 | 0.83 | LHCGR (0.45) | LHCGRFSHRTSHRBRAF | |
| SCHEMBL5026102 | 0.83 | LHCGR (0.53) | LHCGRFSHRTSHRBRAFPDE4A | |
| SCHEMBL5030680 | 0.83 | LHCGR (0.53) | LHCGRFSHRTSHRBRAFPDE4A | |
| SCHEMBL6222413 | 0.83 | LHCGR (0.50) | LHCGRFSHRTSHRBRAFPDE4A | |
| SCHEMBL14285229 | 0.83 | LHCGR (0.73) | LHCGRFSHRTSHRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1171443-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS USEFUL AS LH AGONISTS | AKZO NOBEL NV (NL) | 2005-07-13 | — | — | EP | disclosed |
| US-6841553-B2 | Bicyclic heteroaromatic compounds useful as LH agonists | AKZO NOBEL N.V. (NL) | 2005-01-11 | — | — | US | disclosed |
| US-20030212081-A1 | Bicyclic heteroaromatic compounds useful as LH agonists | MERCK SHARP & DOHME B.V. (NL) | 2003-11-13 | — | — | US | disclosed |
| US-6569863-B1 | Luteinizing hormone (LH) agonists for controlling fertility | AKZO NOBEL NV (NL) | 2003-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212081-A1 | Bicyclic heteroaromatic compounds useful as LH agonists | LHCGR, GNRHR, FSHR | LHCGR 1/4885FSHR 3/4885TSHR 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.